Frontiers in Endocrinology · Nov 17, 2026

Influence of Sequential Timing between Dapagliflozin and Finerenone on Short-term Renal Outcomes in Diabetic Kidney Disease: a real-world observational study from China

By Qiaoying Xu, Rongyun Su, Honggang Wang et al.

Background: This study examined whether the interval between sequential initiation of dapagliflozin and finerenone, on a background of stable renin–angiotensin system inhibitor therapy, influences treatment efficacy and safety in patients with diabetic kidney disease (DKD). Methods: We conducted a retrospective cohort study and stratified patients into a short‑interval group (≤2 weeks) and a long‑interval group (>4 weeks). The primary endpoint was the longitudinal change in urinary albumin‑to‑creatinine ratio (UACR). Secondary endpoints included longitudinal changes in estimated glomerular filtration rate (eGFR) and serum potassium. We also evaluated safety outcomes, specifically hyperkalemia, a clinically relevant decline in eGFR, and treatment discontinuations throughout the combination therapy period. Results: A total of 201 patients were enrolled (104 short-interval; 97 long-interval). The short-interval group demonstrated a significantly faster reduction in UACR than the long-interval group. Subgroup analyses by sex and baseline UACR (median-stratified) yielded consistent results. Chronic kidney disease (CKD)-stratified analyses showed similar findings in CKD stages 3–4, whereas no significant difference was observed in CKD stages 1–2.Both groups showed declining eGFR and rising serum potassium over time. During combination therapy, the short-interval group exhibited significantly greater fluctuations in both parameters than the long-interval group at weeks 4 and 8, with no intergroup differences at week 12. Hyperkalemia occurred in 9.62% (short-interval) and 6.19% (long-interval) of patients, with no fatal events. An eGFR decline >30% was observed in 3.85% and 2.06%, respectively. Treatment discontinuation rates were 5.77% vs. 2.06%, primarily due to temporary finerenone suspension for hyperkalemia. Conclusions: A shorter interval (≤2 weeks) between dapagliflozin and finerenone initiation was associated with greater reductions in UACR within 12 weeks of initiating combination therapy. Nevertheless, rigorous monitoring of eGFR and serum potassium is warranted, especially in patients with lower baseline renal function. These findings necessitate further validation through prospective cohorts.

The paperJournal siteInterventions

AgingResearch.News